Compound medicine for treating Parkinson's disease and preparation method thereof

Abstract

The invention discloses a compound medicine for treating Parkinson's disease and a preparation method thereof, and belongs to the technical field of medicine preparation. The compound medicine disclosed by the invention is prepared from the following components in parts by weight: 250 parts of levodopa, 56 parts of benserazide hydrochloride, 4 to 7 parts of microcrystalline cellulose, 40 to 60 parts of mannitol, 40 to 60 parts of calcium hydrophosphate, 15 to 20 parts of pregelatinized starch, 10 to 15 parts of cross-linked povidone, 10 to 15 parts of povidone, 3 to 7 parts of ethyl cellulose and 3 to 7 parts of magnesium stearate. The compound medicine is small in tablet shape and easy to swallow. And a layer of hydrophobic protective film is formed outside the particles, so that the tablet is high in property, the packaging material requirement of a high-barrier material can be met by using conventional aluminum-plastic packaging, and the tablet has important medical value. Besides, the preparation method disclosed by the invention is simple to operate, the process step of independently drying the levodopa and the benserazide is omitted, and the preparation method has a huge economic value.

Description

[0001] Related patents [0002] This application is a divisional application of a Chinese invention patent application with the application number 202110425424.2, the application date is April 20, 2021, and the invention title is "a compound drug for the treatment of Parkinson's disease and its preparation method". technical field [0003] The invention belongs to the technical field of medicine preparation, in particular to a compound medicine for treating Parkinson's disease and a preparation method thereof. Background technique [0004] Parkinson's disease, like Alzheimer's disease, is a common neurodegenerative disease for which there is currently no effective treatment. Studies have shown that dopamine is lacking in the basal ganglia of patients with Parkinson's disease or Parkinson's syndrome, so current treatments are mainly based on drugs that control dopamine secretion or deep brain stimulation using electrical currents. [0005] Dopamine itself cannot naturally en...

AI Technical Summary

Problems solved by technology

[0006] Chinese invention patent CN101797244B discloses a dopaserazide orally disintegrating tablet. Tablets have not been listed, and only Madopar is clinically available in the domestic market

[0007] U.S. Patent No. 4,424,235 discloses a hydrodynamically balanced controlled-release composition containing levodopa and decarboxylase inhibitors. The method provides a dopa-serazide A preparation method for sustained and controlled release preparations. The weight of the dopaserazide preparation tablet prepared by this method reaches 550 mg, and levodopa and benserazide are required to be granulated separately and are scored tablets. The preparation process is cumbersome and the tablets are relatively large. Jinsen patients have certain risks of swallowing

Images